Grundläggande statistik
| CIK | 1824293 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Vallon Pharmaceuticals Inc
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2025 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| August 20, 2025 |
griinvestorpresentation A New Approach to Inflammatory Diseases NASDAQ: GRI | gribio. |
|
| August 15, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-286072 PROSPECTUS SUPPLEMENT NO. 1 To Prospectus dated April 1, 2025 202,000 Shares of Common Stock 1,186,888 Pre-Funded Warrants to Purchase Up to 1,186,888 Shares of Common Stock 1,388,888 Series E-1 Warrants to Purchase Up to 1,388,888 Shares of Common Stock 1,388,888 Series E-2 Warrants to Purchase Up to 1,388,888 Shares of Common Stock 1,3 |
|
| August 14, 2025 |
Amended and Restated Non-Employee Director Compensa Exhibit 10.2 GRI BIO, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (approved on August 11, 2025) Non-employee members of the board of directors (the “Board”) of GRI Bio, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). This Program has been adopted under the Company’s 2018 Equity Incentive Plan (the |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-40034 GRI BIO, INC. |
|
| August 13, 2025 |
EX-FILING FEES Calculation of Filing Fee Tables Form S-8 (Form Type) GRI Bio, Inc. |
|
| August 13, 2025 |
GRI Bio, Inc. Amended and Restated 2018 Equity Incentive Plan, as Amended. Exhibit 10.1 GRI BIO, INC. 2018 EQUITY INCENTIVE PLAN (As amended and restated) 1. Establishment and Purpose. a. Establishment. GRI Bio, Inc. (formerly known as Vallon Pharmaceuticals, Inc.) (the “Company”) established the GRI Bio, Inc. 2018 Equity Incentive Plan (formerly known as the Vallon Pharmaceuticals, Inc. 2018 Equity Incentive Plan) (the “Plan”) effective as of October 1, 2018. The Plan i |
|
| August 13, 2025 |
As filed with the Securities and Exchange Commission on August 13, 2025 As filed with the Securities and Exchange Commission on August 13, 2025 Registration No. |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| August 13, 2025 |
Exhibit 99.4 Restricted Stock Unit No. GRI BIO, INC. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Company’s Amended and Restated 2018 Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Grant of Restricted Stock Unit Award: 3. Maximum Number of Shares underlying Restricted Stock Unit Award: 4. Vesting of Award: This Restricted Stock Unit Awa |
|
| July 31, 2025 |
Exhibit 99.1 GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a repair response The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns see |
|
| July 31, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer Id |
|
| July 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| June 26, 2025 |
Exhibit 99.1 GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) The Independent Data Monitoring Committee (“IDMC”) has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed Interim results to date demonstrate GRI-0621 to be safe and |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer Id |
|
| May 23, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer Ide |
|
| May 23, 2025 |
GRI BIO, INC. Up to $1,758,934 Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-279348 PROSPECTUS SUPPLEMENT (To Prospectus Supplements Dated May 20, 2024, July 19, 2024, July 26, 2024, December 20, 2024 and May 5, 2025, to Prospectus Dated May 16, 2024) GRI BIO, INC. Up to $1,758,934 Common Stock This prospectus supplement amends, supplements, and supersedes certain information contained in the prospectus supplement dated |
|
| May 15, 2025 |
Exhibit 99.1 GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) Continued momentum with completed patient enrollment for |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-40034 GRI BIO, INC. |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer Ide |
|
| May 5, 2025 |
GRI BIO, INC. Up to $1,670,956 Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-279348 PROSPECTUS SUPPLEMENT (To Prospectus Supplements Dated May 20, 2024, July 19, 2024, July 26, 2024 and December 20, 2024, to Prospectus Dated May 16, 2024) GRI BIO, INC. Up to $1,670,956 Common Stock This prospectus supplement amends, supplements, and supersedes certain information contained in the prospectus supplement dated May 20, 2024 |
|
| May 5, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5 2025 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer Ident |
|
| April 16, 2025 |
Letter from Sadler Gibb & Associates LLC, dated April 15, 2025. Exhibit 16.1 April 15, 2025 Securities and Exchange Commission 100 F Street, N.W. Washington, D.C. 20549 Ladies and Gentlemen, We have read Item 4.01 of Form 8-K dated April 15, 2025 of GRI Bio, Inc., and are in agreement with the statements contained therein as it regards our firm. We have no basis to agree or disagree with other statements of the registrant contained in Item 4.01. Sincerely, /s/ |
|
| April 16, 2025 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2025 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer I |
|
| April 2, 2025 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 1, 2025, between GRI Bio, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and con |
|
| April 2, 2025 |
Form of Placement Agent Warrant. Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Issue Date: , 2025 Initial Exercise Date: , 2025 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| April 2, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer Id |
|
| April 2, 2025 |
Exhibit 4.2 SERIES E-[1][2][3] COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Issue Date: , 2025 Initial Exercise Date: , 2025 THIS SERIES E-[1][2][3] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time |
|
| April 2, 2025 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Issue Date: , 2025 Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| April 2, 2025 |
GRI Bio Announces Pricing of $5.0 Million Public Offering EX-99.1 6 ex991aprilofferingpressre.htm EX-99.1 Exhibit 99.1 GRI Bio Announces Pricing of $5.0 Million Public Offering LA JOLLA, CA, April 1, 2025 (GLOBE NEWSWIRE) - GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today |
|
| April 2, 2025 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-286072 PROSPECTUS 202,000 Shares of Common Stock 1,186,888 Pre-Funded Warrants to Purchase Up to 1,186,888 Shares of Common Stock 1,388,888 Series E-1 Warrants to Purchase Up to 1,388,888 Shares of Common Stock 1,388,888 Series E-2 Warrants to Purchase Up to 1,388,888 Shares of Common Stock 1,388,888 Series E-3 Warrants to Purchase Up to 1,388, |
|
| March 26, 2025 |
GRI BIO, INC. 2223 AVENIDA DE LA PLAYA, SUITE 208 LA JOLLA, CA 92037 GRI BIO, INC. 2223 AVENIDA DE LA PLAYA, SUITE 208 LA JOLLA, CA 92037 VIA EDGAR March 26, 2025 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Re: GRI Bio, Inc. Registration Statement on Form S-1, as amended (File No. 333-286072) Request for Acceleration of Effective Date Ladies and Gentl |
|
| March 26, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) GRI Bio, Inc. (Exact Name of Each Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Code Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Eq |
|
| March 26, 2025 |
As filed with the Securities and Exchange Commission on March 26, 2025. As filed with the Securities and Exchange Commission on March 26, 2025. Registration No. 333-286072 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-4369909 (State or other jurisdiction of incorporation or o |
|
| March 26, 2025 |
Exhibit 4.21 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Issue Date: , 2025 [Initial Exercise Date: , 2025]1 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time o |
|
| March 26, 2025 |
March 26, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, DC 20549 Re: GRI Bio, Inc. Registration Statement on Form S-1 (File No. 333-286072), as amended – Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best efforts basis in an offering pursuant to the regi |
|
| March 25, 2025 |
Exhibit 4.23 SERIES E-[1][2][3] COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Issue Date: , 2025 [Initial Exercise Date: , 2025]1 THIS SERIES E-[1][2][3] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any |
|
| March 25, 2025 |
Exhibit 4.22 PRE-FUNDED COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Issue Date: , 2025 Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after th |
|
| March 25, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) GRI Bio, Inc. (Exact Name of Each Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Code Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Eq |
|
| March 25, 2025 |
orm of Securities Purchase Agreement. Exhibit 10.25 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March [●], 2025, between GRI Bio, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set for |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 24, 2025. As filed with the Securities and Exchange Commission on March 24, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-4369909 (State or other jurisdiction of incorporation or organization) (Primary Sta |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer I |
|
| March 17, 2025 |
Exhibit 99.1 GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF") Interim data and topline data readouts from Phase 2a biomarker study expected in Q2 2025 and Q3 2025, respectively Cash runway expected to fund operations into Q2 2025, including interim data readout fro |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-400 |
|
| March 14, 2025 |
Confidential Treatment Requested by GRI Bio, Inc. Pursuant to 17 C.F.R. Section 200.83 Confidential Treatment Requested by GRI Bio, Inc. Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the Securities and Exchange Commission on March 14, 2025. This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCH |
|
| March 14, 2025 |
Amended and Restated Certificate of Incorporation, as amended Exhibit 3.1 Delaware The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF “VALLON PHARMACEUTICALS, INC.”, FILED IN THIS OFFICE ON THE TENTH DAY OF FEBRUARY, A.D. 2021, AT 1:14 O’CLOCK P.M. 6705195 8100 Authentication: 202482772 SR# 20210402453 Date: 02-10-21 You may verify this c |
|
| March 14, 2025 |
Exhibit 4.28 DESCRIPTION OF THE REGISTRANT’S SECURITIES The following summary of the material terms of the capital stock of GRI Bio, Inc. (formerly Vallon Pharmaceuticals, Inc.) is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our amended and restated certificate of incorporation, as amended (“Amended and Restated Certifica |
|
| March 14, 2025 |
Exhibit 19 INSIDER TRADING AND SECURITIES LAW COMPLIANCE POLICY OF GRI BIO, INC. Adopted by the Board of Directors on November 6, 2020 I. BACKGROUND The Board of Directors of GRI Bio, Inc. (“GRI” or the “Company”) has adopted this Insider Trading and Securities Law Compliance Policy relating to the trading of GRI securities as well as the securities of publicly-traded companies with whom GRI has a |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer I |
|
| March 11, 2025 |
GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule Exhibit 99.1 GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule LA JOLLA, CA, March 11, 2025 (GLOBE NEWSWIRE) - GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it received notice on Marc |
|
| February 19, 2025 |
Exhibit 99.1 GRI Bio Announces Reverse Stock Split GRI’s common stock is expected to begin trading on a post-split adjusted basis on February 24, 2025 LA JOLLA, CA, February 19, 2025 – GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmu |
|
| February 19, 2025 |
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of GRI Bio, Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION The corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certified that: FIRST. The name of the corporation is GRI Bio, Inc. (the “Corporation”). SECOND. The Amended and Restated Certificate of Incorporation of the Corporation, as amended to date, is hereby fur |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employe |
|
| February 11, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employe |
|
| January 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| January 6, 2025 |
As filed with the Securities and Exchange Commission on January 6, 2025 As filed with the Securities and Exchange Commission on January 6, 2025 Registration No. |
|
| January 6, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) GRI Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0. |
|
| December 20, 2024 |
GRI BIO, INC. Up to $322,468 Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-279348 PROSPECTUS SUPPLEMENT (To Prospectus Supplements Dated May 20, 2024, July 19, 2024 and July 26, 2024, to Prospectus Dated May 16, 2024) GRI BIO, INC. Up to $322,468 Common Stock This prospectus supplement amends, supplements, and supersedes certain information contained in the prospectus supplement dated May 20, 2024, and its accompanyin |
|
| December 20, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employe |
|
| November 20, 2024 |
GRI BIO, INC. 2223 AVENIDA DE LA PLAYA, SUITE 208 LA JOLLA, CA 92037 GRI BIO, INC. 2223 AVENIDA DE LA PLAYA, SUITE 208 LA JOLLA, CA 92037 November 20, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: GRI Bio, Inc. Registration Statement on Form S-3 Filed November 14, 2024 File No. 333-283234 (the “Registration Statement”) Acceleration Request Ladies and Gent |
|
| November 15, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280323 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus dated June 26, 2024 60,000 Shares of Common Stock 2,125,793 Pre-Funded Warrants to Purchase Up to 2,125,793 Shares of Common Stock 2,185,793 Series C-1 Warrants to Purchase Up to 2,185,793 Shares of Common Stock 2,185,793 Series C-2 Warrants to Purchase Up to 2,185,793 Shares of Common Stock 153, |
|
| November 14, 2024 |
Exhibit 99.1 GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis $13.9 million in gross proceeds raised since the beginning of 2024 extending expected cash runway into mid Q1 2025 and through interim data readout from GRI-0621 Phase 2a biomarker study Topline data of GRI-062 |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employe |
|
| November 14, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) GRI Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table I - Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry For |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-40034 GRI BIO, INC. |
|
| November 14, 2024 |
As filed with the Securities and Exchange Commission on November 14, 2024 As filed with the Securities and Exchange Commission on November 14, 2024 Registration No. |
|
| October 24, 2024 |
Exhibit 99.1 GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024 Proceeds from recent exercise of warrants estimated to extend cash runway into mid Q1 2025, including interim data readout from Phase 2a biomarker study of lead program, GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) Current treatment options for IPF are limited with only 2 approve |
|
| October 24, 2024 |
Financial Statements and Exhibits, Other Events . UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employ |
|
| October 22, 2024 |
. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employ |
|
| October 22, 2024 |
GRI Bio Announces Exercise of Warrants Exhibit 99.1 GRI Bio Announces Exercise of Warrants LA JOLLA, CA, October 21, 2024 (GLOBE NEWSWIRE) - GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases,today announced that it has entered into definitive agreements for the ex |
|
| October 22, 2024 |
Form of Series D-2 Common Warrant. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 22, 2024 |
Form of Repricing Letter Agreement. Exhibit 10.1 GRI BIO, INC. October 21, 2024 Holder of Common Stock Purchase Warrants Issued in February 2024 Re: Inducement Offer to Exercise Common Stock Purchase Warrants Issued in February 2024 Dear Holder: GRI Bio, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) the opportunity to receive (i) new warrants to purchase shares of the Company’s common stock |
|
| October 22, 2024 |
Form of Series D-1 Common Warrant. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 22, 2024 |
Form of Placement Agent Warrant. Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FOR 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Nu |
|
| September 11, 2024 |
Filed pursuant to 424(b)(3) Registration No. 333-280323 PROSPECTUS SUPPLEMENT NO. 2 To Prospectus dated June 26, 2024 60,000 Shares of Common Stock 2,125,793 Pre-Funded Warrants to Purchase Up to 2,125,793 Shares of Common Stock 2,185,793 Series C-1 Common Warrants to Purchase Up to 2,185,793 Shares of Common Stock 2,185,793 Series C-2 Common Warrants to Purchase Up to 2,185,793 Shares of Common S |
|
| September 11, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employ |
|
| September 11, 2024 |
Filed pursuant to 424(b)(3) Registration No. 333-276205 PROSPECTUS SUPPLEMENT NO. 8 To Prospectus dated February 1, 2024 25,419 Shares of Common Stock 359,196 Pre-Funded Warrants to Purchase Up to 359,196 Shares of Common Stock 384,615 Series B-1 Common Warrants to Purchase Up to 384,615 Shares of Common Stock 384,615 Series B-2 Common Warrants to Purchase Up to 384,615 Shares of Common Stock 359, |
|
| September 6, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employe |
|
| August 28, 2024 |
45,431 Shares of Common Stock Offered by the Selling Stockholder Filed Pursuant to Rule 424(b)(3) Registration No. 333-274972 PROSPECTUS SUPPLEMENT NO. 11 To Prospectus dated December 15, 2023 45,431 Shares of Common Stock Offered by the Selling Stockholder This prospectus supplement No. 11 supplements the prospectus dated December 15, 2023 (the “Prospectus”), which covers the offer and resale by the selling stockholder identified in this prospectus of up to an |
|
| August 28, 2024 |
Filed pursuant to 424(b)(3) Registration No. 333-280323 PROSPECTUS SUPPLEMENT NO. 1 To Prospectus dated June 26, 2024 60,000 Shares of Common Stock 2,125,793 Pre-Funded Warrants to Purchase Up to 2,125,793 Shares of Common Stock 2,185,793 Series C-1 Common Warrants to Purchase Up to 2,185,793 Shares of Common Stock 2,185,793 Series C-2 Common Warrants to Purchase Up to 2,185,793 Shares of Common S |
|
| August 28, 2024 |
Filed pursuant to 424(b)(3) Registration No. 333-276205 PROSPECTUS SUPPLEMENT NO. 7 To Prospectus dated February 1, 2024 25,419 Shares of Common Stock 359,196 Pre-Funded Warrants to Purchase Up to 359,196 Shares of Common Stock 384,615 Series B-1 Common Warrants to Purchase Up to 384,615 Shares of Common Stock 384,615 Series B-2 Common Warrants to Purchase Up to 384,615 Shares of Common Stock 359, |
|
| August 23, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-40034 GRI BIO, INC. |
|
| August 14, 2024 |
A New Approach to Inflammatory Diseases NASDAQ: GRI | gribio.com August 2024 Corporate Presentation Forward Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of GRI Bio, Inc. (“GRI” or the “Company”). This presentation contains “forward-looking statements” within the meaning of the “safe harbor” p |
|
| August 14, 2024 |
Exhibit 99.1 GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout of Phase 2a biomarker study on track for Q4 2024 and topline data on track for Q1 2025 LA JOLLA, CA, August 13, 2024 (GLOBE NEWSWIRE) - GRI Bio, Inc. (NASDAQ: GRI |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| July 26, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer Id |
|
| July 26, 2024 |
GRI BIO, INC. Up to $2,644,609 Common Stock 424B5 1 gri-atmxprospectussuppleme.htm 424B5 Filed pursuant to Rule 424(b)(5) Registration No. 333-279348 PROSPECTUS SUPPLEMENT (To Prospectus Supplements Dated May 20, 2024 and July 19, 2024, to Prospectus Dated May 16, 2024) GRI BIO, INC. Up to $2,644,609 Common Stock This prospectus supplement amends, supplements, and supersedes certain information contained in the prospectus supplement dated M |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| July 19, 2024 |
GRI BIO, INC. Up to $1,038,886 Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-279348 PROSPECTUS SUPPLEMENT (To Prospectus Supplement Dated May 20, 2024, to Prospectus Dated May 16, 2024) GRI BIO, INC. Up to $1,038,886 Common Stock This prospectus supplement amends, supplements, and supersedes certain information contained in the prospectus supplement dated May 20, 2024, and its accompanying prospectus dated May 16, 2024 |
|
| July 19, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer Id |
|
| July 8, 2024 |
GRI Bio Regains Compliance with Nasdaq Exhibit 99.1 GRI Bio Regains Compliance with Nasdaq LA JOLLA, CA, July 8, 2024 (GLOBE NEWSWIRE) - GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it received notice on July 2, 2024 from The Nasdaq Stoc |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer Ide |
|
| June 27, 2024 |
Form of Placement Agent Warrant Exhibit 4.4 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Issue Date: June 28, 2024 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder |
|
| June 27, 2024 |
Exhibit 4.1 Exhibit A-3 PRE-FUNDED COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Issue Date: June 28, 2024 Initial Exercise Date: June 28, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, a |
|
| June 27, 2024 |
GRI Bio Announces Pricing of $4.0 Million Public Offering Exhibit 99.1 GRI Bio Announces Pricing of $4.0 Million Public Offering LA JOLLA, CA, June 27, 2024 (GLOBE NEWSWIRE) - GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the pricing of a public offering of an |
|
| June 27, 2024 |
Form of Series C-2 Common Warrant. Exhibit 4.3 Exhibit A-2 SERIES C-2 COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Issue Date: June 28, 2024 THIS SERIES C-2 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholde |
|
| June 27, 2024 |
Exhibit 4.2 Exhibit A-1 SERIES C-1 COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Issue Date: June 28, 2024 THIS SERIES C-1 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholde |
|
| June 27, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer Id |
|
| June 27, 2024 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 26, 2024, between GRI Bio, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth |
|
| June 27, 2024 |
Filed pursuant to 424(b)(4) Registration No. 333-280323 PROSPECTUS 60,000 Shares of Common Stock 2,125,793 Pre-Funded Warrants to Purchase Up to 2,125,793 Shares of Common Stock 2,185,793 Series C-1 Warrants to Purchase Up to 2,185,793 Shares of Common Stock 2,185,793 Series C-2 Warrants to Purchase Up to 2,185,793 Shares of Common Stock 153,006 Placement Agent Warrants to Purchase Up to 153,006 S |
|
| June 26, 2024 |
Exhibit 4.21 PRE-FUNDED COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Issue Date: , 2024 Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after th |
|
| June 26, 2024 |
Exhibit 4.22 SERIES C-1 COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Issue Date: , 2024 Initial Exercise Date: , 2024 THIS SERIES C-1 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after th |
|
| June 26, 2024 |
Form of Securities Purchase Agreement. Exhibit 10.38 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [ ], 2024, between GRI Bio, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in |
|
| June 26, 2024 |
Exhibit 4.23 SERIES C-2 COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Issue Date: , 2024 Initial Exercise Date: , 2024 THIS SERIES C-2 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after th |
|
| June 26, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) GRI Bio, Inc. (Exact Name of Each Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee E |
|
| June 26, 2024 |
Form of Placement Agent Warrant. Exhibit 4.24 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Issue Date: , 2024 Initial Exercise Date: , 2024 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on o |
|
| June 26, 2024 |
As filed with the Securities and Exchange Commission on June 26, 2024. As filed with the Securities and Exchange Commission on June 26, 2024. Registration No. 333-280323 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-4369909 (State or other jurisdiction of incorporation or or |
|
| June 26, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) GRI Bio, Inc. (Exact Name of Each Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee E |
|
| June 26, 2024 |
As filed with the Securities and Exchange Commission on June 25, 2024. As filed with the Securities and Exchange Commission on June 25, 2024. Registration No. 333-280323 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-4369909 (State or other jurisdiction of incorporation or or |
|
| June 25, 2024 |
GRI BIO, INC. 2223 AVENIDA DE LA PLAYA, SUITE 208 LA JOLLA, CA 92037 GRI BIO, INC. 2223 AVENIDA DE LA PLAYA, SUITE 208 LA JOLLA, CA 92037 VIA EDGAR June 25, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Re: GRI Bio, Inc. Registration Statement on Form S-1 (Reg. No. 333-280323) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to |
|
| June 25, 2024 |
June 25, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: GRI Bio, Inc. Registration Statement on Form S-1 (Registration No. 333-280323), as amended - Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best efforts basis in an offering pursuant to the |
|
| June 20, 2024 |
As filed with the Securities and Exchange Commission on June 18, 2024. As filed with the Securities and Exchange Commission on June 18, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-4369909 (State or other jurisdiction of incorporation or organization) (Primary Stan |
|
| June 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) GRI Bio, Inc. (Exact Name of Each Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee E |
|
| June 20, 2024 |
Amended and Restated Certificate of Incorporation, as amended. Exhibit 3.1 Delaware The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF “VALLON PHARMACEUTICALS, INC.”, FILED IN THIS OFFICE ON THE TENTH DAY OF FEBRUARY, A.D. 2021, AT 1:14 O’CLOCK P.M. 6705195 8100 Authentication: 202482772 SR# 20210402453 Date: 02-10-21 You may verify this c |
|
| June 18, 2024 |
Filed pursuant to 424(b)(3) Registration No. 333-276205 PROSPECTUS SUPPLEMENT NO. 6 To Prospectus dated February 1, 2024 25,419 Shares of Common Stock 359,196 Pre-Funded Warrants to Purchase Up to 359,196 Shares of Common Stock 384,615 Series B-1 Common Warrants to Purchase Up to 384,615 Shares of Common Stock 384,615 Series B-2 Common Warrants to Purchase Up to 384,615 Shares of Common Stock 359, |
|
| June 18, 2024 |
45,431 Shares of Common Stock Offered by the Selling Stockholder Filed pursuant to 424(b)(3) Registration No. 333-274972 PROSPECTUS SUPPLEMENT NO. 10 To Prospectus dated December 15, 2023 45,431 Shares of Common Stock Offered by the Selling Stockholder This prospectus supplement No. 10 supplements the prospectus dated December 15, 2023 (the “Prospectus”), which covers the offer and resale by the selling stockholder identified in this prospectus of up to an aggr |
|
| June 18, 2024 |
by and between the Company and Albert Exhibit 10.1 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This Amendment No. 1 (“Amendment No. 1”) is entered into between Albert Agro, Ph.D (“Executive”) and GRI Bio, Inc. (the “Company”) to amend Executive’s Employment Agreement with the Company (the “Employment Agreement’). This Amendment No. 1 is effective as of June 17, 2024 (the “Effective Date”). WHEREAS, the Company has employed Executive pursu |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer Id |
|
| June 17, 2024 |
Filed pursuant to 424(b)(3) Registration No. 333-276205 PROSPECTUS SUPPLEMENT NO. 5 To Prospectus dated February 1, 2024 330,450 Shares of Common Stock 4,669,550 Pre-Funded Warrants to Purchase Up to 4,669,550 Shares of Common Stock 5,000,000 Series B-1 Common Warrants to Purchase Up to 5,000,000 Shares of Common Stock 5,000,000 Series B-2 Common Warrants to Purchase Up to 5,000,000 Shares of Comm |
|
| June 17, 2024 |
590,603 Shares of Common Stock Offered by the Selling Stockholder Filed pursuant to 424(b)(3) Registration No. 333-274972 PROSPECTUS SUPPLEMENT NO. 9 To Prospectus dated December 15, 2023 590,603 Shares of Common Stock Offered by the Selling Stockholder This prospectus supplement No. 9 supplements the prospectus dated December 15, 2023 (the “Prospectus”), which covers the offer and resale by the selling stockholder identified in this prospectus of up to an aggre |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer Id |
|
| June 14, 2024 |
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of GRI Bio, Inc. Exhibit 3.1 |
|
| June 14, 2024 |
Exhibit 99.1 GRI Bio Announces Reverse Stock Split GRI’s common stock is expected to begin trading on a post-split adjusted basis on June 18, 2024 LA JOLLA, CA, June 14, 2024 – GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune disea |
|
| June 7, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer Ide |
|
| May 31, 2024 |
590,603 Shares of Common Stock Offered by the Selling Stockholder Filed pursuant to 424(b)(3) Registration No. 333-274972 PROSPECTUS SUPPLEMENT NO. 8 To Prospectus dated December 15, 2023 590,603 Shares of Common Stock Offered by the Selling Stockholder This prospectus supplement No. 8 supplements the prospectus dated December 15, 2023 (the “Prospectus”), which covers the offer and resale by the selling stockholder identified in this prospectus of up to an aggre |
|
| May 31, 2024 |
Filed pursuant to 424(b)(3) Registration No. 333-276205 PROSPECTUS SUPPLEMENT NO. 4 To Prospectus dated February 1, 2024 330,450 Shares of Common Stock 4,669,550 Pre-Funded Warrants to Purchase Up to 4,669,550 Shares of Common Stock 5,000,000 Series B-1 Common Warrants to Purchase Up to 5,000,000 Shares of Common Stock 5,000,000 Series B-2 Common Warrants to Purchase Up to 5,000,000 Shares of Comm |
|
| May 22, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer Ide |
|
| May 21, 2024 |
Filed pursuant to 424(b)(3) Registration No. 333-276205 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus dated February 1, 2024 330,450 Shares of Common Stock 4,669,550 Pre-Funded Warrants to Purchase Up to 4,669,550 Shares of Common Stock 5,000,000 Series B-1 Common Warrants to Purchase Up to 5,000,000 Shares of Common Stock 5,000,000 Series B-2 Common Warrants to Purchase Up to 5,000,000 Shares of Comm |
|
| May 21, 2024 |
590,603 Shares of Common Stock Offered by the Selling Stockholder Filed pursuant to 424(b)(3) Registration No. 333-274972 PROSPECTUS SUPPLEMENT NO. 7 To Prospectus dated December 15, 2023 590,603 Shares of Common Stock Offered by the Selling Stockholder This prospectus supplement No. 7 supplements the prospectus dated December 15, 2023 (the “Prospectus”), which covers the offer and resale by the selling stockholder identified in this prospectus of up to an aggre |
|
| May 20, 2024 |
Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT May 20, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: GRI Bio, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in this Agreement |
|
| May 20, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer Ide |
|
| May 20, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-279348 Prospectus Supplement (To Prospectus dated May 16, 2024) Up to $961,579 Common Stock We have entered into an At the Market Offering Agreement (the “Sales Agreement”), with H.C. Wainwright & Co., LLC (“Wainwright”or “sales agent”) relating to the sale of shares of our common stock, par value $0.0001 per share, offered by this prospectus s |
|
| May 14, 2024 |
GRI BIO, INC. 2223 AVENIDA DE LA PLAYA, SUITE 208 LA JOLLA, CA 92037 GRI BIO, INC. 2223 AVENIDA DE LA PLAYA, SUITE 208 LA JOLLA, CA 92037 May 14, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards Re: GRI Bio, Inc. Registration Statement on Form S-3 Filed May 10, 2024 File No. 333-279348 (the “Registration Statement”) Acceleration Request Ladies and Gentlemen: In |
|
| May 14, 2024 |
590,603 Shares of Common Stock Offered by the Selling Stockholder Filed pursuant to 424(b)(3) Registration No. 333-274972 PROSPECTUS SUPPLEMENT NO. 6 To Prospectus dated December 15, 2023 590,603 Shares of Common Stock Offered by the Selling Stockholder This prospectus supplement No. 6 supplements the prospectus dated December 15, 2023 (the “Prospectus”), which covers the offer and resale by the selling stockholder identified in this prospectus of up to an aggre |
|
| May 14, 2024 |
Filed pursuant to 424(b)(3) Registration No. 333-276205 PROSPECTUS SUPPLEMENT NO. 2 To Prospectus dated February 1, 2024 330,450 Shares of Common Stock 4,669,550 Pre-Funded Warrants to Purchase Up to 4,669,550 Shares of Common Stock 5,000,000 Series B-1 Common Warrants to Purchase Up to 5,000,000 Shares of Common Stock 5,000,000 Series B-2 Common Warrants to Purchase Up to 5,000,000 Shares of Comm |
|
| May 13, 2024 |
Exhibit 99.1 GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update Interim data readout of Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) expected Q3 2024 and topline data on track for Q4 2024 Ongoing progress of Investigational New Drug (IND) enabling studies in systemic lupus erythematosus (SLE) prog |
|
| May 13, 2024 |
griinvestorpresenation0 A New Approach to Inflammatory Diseases NASDAQ: GRI | gribio. |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer Ide |
|
| May 10, 2024 |
Form of Subordinated Indenture Exhibit 4.5 GRI BIO, INC. Issuer AND [], Trustee INDENTURE Dated as of [] Subordinated Debt Securities TABLE OF CONTENTS1 Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms. 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.1 Designation and Terms of Securities. 5 Section 2.2 Form of Securities and Trustee’s Certificate. 7 Section 2.3 |
|
| May 10, 2024 |
As filed with the Securities and Exchange Commission on May 10, 2024 As filed with the Securities and Exchange Commission on May 10, 2024 Registration No. |
|
| May 10, 2024 |
Exhibit 4.4 GRI BIO, INC. Issuer AND [], Trustee INDENTURE Dated as of [] Senior Debt Securities TABLE OF CONTENTS1 Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms. 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.1 Designation and Terms of Securities. 5 Section 2.2 Form of Securities and Trustee’s Certificate. 7 Section 2.3 Denom |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-40034 GRI BIO, INC. |
|
| May 10, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) GRI Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| April 1, 2024 |
Exhibit 99.1 GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update Ongoing Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) with interim data expected H1 2024 and topline data expected H2 2024 GRI-0803 systemic lupus erythematosus (SLE) program advancing towards completion of Investigational New Drug (IND) A |
|
| April 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer Id |
|
| March 28, 2024 |
Exhibit 4.27 DESCRIPTION OF THE REGISTRANT’S SECURITIES The following summary of the material terms of the capital stock of GRI Bio, Inc. (formerly Vallon Pharmaceuticals, Inc.) is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our amended and restated certificate of incorporation, as amended (“Amended and Restated Certifica |
|
| March 28, 2024 |
590,603 Shares of Common Stock Offered by the Selling Stockholder Filed pursuant to 424(b)(3) Registration No. 333-274972 PROSPECTUS SUPPLEMENT NO. 5 To Prospectus dated December 15, 2023 590,603 Shares of Common Stock Offered by the Selling Stockholder This prospectus supplement No. 5 supplements the prospectus dated December 15, 2023 (the “Prospectus”), which covers the offer and resale by the selling stockholder identified in this prospectus of up to an aggre |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-400 |
|
| March 28, 2024 |
Filed pursuant to 424(b)(3) Registration No. 333-276205 PROSPECTUS SUPPLEMENT NO. 1 To Prospectus dated February 1, 2024 330,450 Shares of Common Stock 4,669,550 Pre-Funded Warrants to Purchase Up to 4,669,550 Shares of Common Stock 5,000,000 Series B-1 Common Warrants to Purchase Up to 5,000,000 Shares of Common Stock 5,000,000 Series B-2 Common Warrants to Purchase Up to 5,000,000 Shares of Comm |
|
| March 28, 2024 |
Exhibit 10.26 STANDARD OFFICE LEASE LA JOLLA SHORES PLAZA THIS STANDARD OFFICE LEASE (“Lease”) is entered into effective as of March 2, 2018 (“Effective Date”), between LA JOLLA SHORES PLAZA, LLC, a California limited liability company (“Landlord”), and GRI BIO, INC., a Delaware Corporation (“Tenant”). Landlord and Tenant agree as follows: BASIC LEASE PROVISIONS The provisions set forth in Paragra |
|
| March 28, 2024 |
Amended and Restated Certificate of Incorporation Exhibit 3.1 Delaware The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF “VALLON PHARMACEUTICALS, INC.”, FILED IN THIS OFFICE ON THE TENTH DAY OF FEBRUARY, A.D. 2021, AT 1:14 O’CLOCK P.M. 6705195 8100 Authentication: 202482772 SR# 20210402453 Date: 02-10-21 You may verify this c |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* GRI BIO, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 3622AW106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 2, 2024 |
Form of Series B-1 Common Warrant Exhibit 4.2 FORM OF SERIES B-1 COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Initial Exercise Date: , 2024 Issue Date: February [●], 2024 THIS SERIES B-1 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any |
|
| February 2, 2024 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-276205 PROSPECTUS 330,450 Shares of Common Stock 4,669,550 Pre-Funded Warrants to Purchase Up to 4,669,550 Shares of Common Stock 5,000,000 Series B-1 Common Warrants to Purchase Up to 5,000,000 Shares of Common Stock 5,000,000 Series B-2 Common Warrants to Purchase Up to 5,000,000 Shares of Common Stock 4,669,550 Shares of Common Stock underly |
|
| February 2, 2024 |
GRI Bio Announces Pricing of $5.5 Million Public Offering Exhibit 99.1 GRI Bio Announces Pricing of $5.5 Million Public Offering LA JOLLA, CA, Feb. 2, 2024 (GLOBE NEWSWIRE) - GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the pricing of its “reasonable best eff |
|
| February 2, 2024 |
Form of Series B-2 Common Warrant Exhibit 4.3 FORM OF SERIES B-2 COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Initial Exercise Date: , 2024 Issue Date: February [●], 2024 THIS SERIES B-2 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any |
|
| February 2, 2024 |
590,603 Shares of Common Stock Offered by the Selling Stockholder Filed pursuant to 424(b)(3) Registration No. 333-274972 PROSPECTUS SUPPLEMENT NO. 4 To Prospectus dated December 15, 2023 590,603 Shares of Common Stock Offered by the Selling Stockholder This prospectus supplement No. 4 supplements the prospectus dated December 15, 2023 (the “Prospectus”), which covers the offer and resale by the selling stockholder identified in this prospectus of up to an aggre |
|
| February 2, 2024 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| February 2, 2024 |
Exhibit 4.1 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Initial Exercise Date: , 2024 Issue Date: February [●], 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any |
|
| February 2, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 1, 2024, between GRI Bio, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set for |
|
| February 2, 2024 |
Exhibit 10.2 February 1, 2024 GRI Bio, Inc. Attention: W. Marc Hertz, Ph.D 2223 Avenida de la Playa, Suite 208 La Jolla, CA 92037 Dear Dr. Hertz: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (“A.G.P.” or the “Placement Agent”) and GRI Bio, Inc., a Delaware corporation (the “Company”), that the Placement Agent shall serve as the exclusive placement |
|
| February 2, 2024 |
Exhibit 10.3 FORM OF LOCK-UP AGREEMENT February 1, 2024 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, New York 10022 Re: GRI Bio, Inc., Proposed Offering Ladies and Gentlemen: The undersigned understands that you (“AGP” or the “Placement Agent”) propose to enter into a Placement Agency Agreement (the “Placement Agency Agreement”) providing for the offer and sale (the “Of |
|
| January 31, 2024 |
Form of Securities Purchase Agreement. Exhibit 10.37 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2024, between GRI Bio, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in thi |
|
| January 31, 2024 |
As filed with the Securities and Exchange Commission on January 31, 2024. As filed with the Securities and Exchange Commission on January 31, 2024. Registration No. 333-276205 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-4369909 (State or other jurisdiction of incorporation or |
|
| January 31, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) GRI Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table I - Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Fees T |
|
| January 31, 2024 |
Form of Placement Agent Agreement. Exhibit 10.38 January [], 2024 GRI Bio, Inc. Attention: W. Marc Hertz, Ph.D 2223 Avenida de la Playa, Suite 208 La Jolla, CA 92037 Dear Dr. Hertz: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (“A.G.P.” or the “Placement Agent”) and GRI Bio, Inc., a Delaware corporation (the “Company”), that the Placement Agent shall serve as the exclusive placemen |
|
| January 31, 2024 |
As filed with the Securities and Exchange Commission on January 30, 2024. As filed with the Securities and Exchange Commission on January 30, 2024. Registration No. 333-276205 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-4369909 (State or other jurisdiction of incorporation or |
|
| January 31, 2024 |
Form of Series B-1 Common Warrant. Exhibit 4.25 SERIES B-1 COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Initial Exercise Date: , 2024 Issue Date: January [●], 2024 THIS SERIES B-1 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| January 31, 2024 |
Form of Series B-2 Common Warrant. Exhibit 4.26 SERIES B-2 COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Initial Exercise Date: , 2024 Issue Date: January [●], 2024 THIS SERIES B-2 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| January 31, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) GRI Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table I - Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Fees T |
|
| January 31, 2024 |
Exhibit 4.24 PRE-FUNDED COMMON STOCK PURCHASE WARRANT GRI BIO, INC. Warrant Shares: Initial Exercise Date: January [●], 2024 Issue Date: January [●], 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at a |
|
| January 30, 2024 |
January 31, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Daniel Crawford Re: GRI Bio, Inc. Registration Statement on Form S-1 File No. 333-276205 Ladies and Gentlemen: In accordance with Rule 461 of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended (the “Act”), A. |
|
| January 30, 2024 |
590,603 Shares of Common Stock Offered by the Selling Stockholder Filed Pursuant to Rule 424(b)(3) Registration No. 333-274972 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus dated December 15, 2023 590,603 Shares of Common Stock Offered by the Selling Stockholder This prospectus supplement No. 3 supplements the prospectus dated December 15, 2023 (the “Prospectus”), which covers the offer and resale by the selling stockholder identified in this prospectus of up to an |
|
| January 30, 2024 |
GRI BIO, INC. 2223 AVENIDA DE LA PLAYA, SUITE 208 LA JOLLA, CA 92037 GRI BIO, INC. 2223 AVENIDA DE LA PLAYA, SUITE 208 LA JOLLA, CA 92037 January 31, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Daniel Crawford Re: GRI Bio, Inc. Registration Statement on Form S-1, as amended File No. 333-276205 (the “Registration Statement”) Acceleration Request Ladies and Gentlemen: In a |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| January 30, 2024 |
ficate of Amendment to the Amended and Restated Certificate of Incorporation. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION The corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certified that: FIRST: The name of the corporation is GRI Bio, Inc. (the “Corporation”). SECOND: The Amended and Restated Certificate of Incorporation of the Corporation, as amended to date, is hereby fur |
|
| January 30, 2024 |
Exhibit 99.1 GRI Bio Announces Reverse Stock Split GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 30, 2024 LA JOLLA, CA, January 26, 2024 – GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune |
|
| January 19, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| January 19, 2024 |
4,134,201 Shares of Common Stock Offered by the Selling Stockholder Filed Pursuant to Rule 424(b)(3) Registration No. 333-274972 PROSPECTUS SUPPLEMENT NO. 2 To Prospectus dated December 15, 2023 4,134,201 Shares of Common Stock Offered by the Selling Stockholder This prospectus supplement No. 2 supplements the prospectus dated December 15, 2023 (the “Prospectus”), which covers the offer and resale by the selling stockholder identified in this prospectus of up to a |
|
| January 16, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| January 16, 2024 |
A New Approach to Inflammatory Diseases NASDAQ: GRI | gribio.com January 2024 Corporate Presentation Forward Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of GRI Bio, Inc. (“GRI” or the “Company”). This presentation contains “forward-looking statements” within the meaning of the "safe harbor" |
|
| January 8, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| January 8, 2024 |
4,134,201 Shares of Common Stock Offered by the Selling Stockholder Filed Pursuant to Rule 424(b)(3) Registration No. 333-274972 PROSPECTUS SUPPLEMENT NO. 1 To Prospectus dated December 15, 2023 4,134,201 Shares of Common Stock Offered by the Selling Stockholder This prospectus supplement No. 1 supplements the prospectus dated December 15, 2023 (the “Prospectus”), which covers the offer and resale by the selling stockholder identified in this prospectus of up to a |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| December 21, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) GRI Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table I - Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Fees T |
|
| December 21, 2023 |
As filed with the Securities and Exchange Commission on December 21, 2023. As filed with the Securities and Exchange Commission on December 21, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-4369909 (State or other jurisdiction of incorporation or organization) (Primary |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| December 15, 2023 |
4,134,201 Shares of Common Stock Offered by the Selling Stockholder Filed pursuant to 424(b)(3) Registration No. 333-274972 PROSPECTUS 4,134,201 Shares of Common Stock Offered by the Selling Stockholder This prospectus covers the offer and resale by the selling stockholder identified in this prospectus of up to an aggregate of 4,134,201 shares of our common stock, $0.0001 par value per share (the “Common Stock”), consisting of (i) 1,269,210 shares of Common Stock |
|
| December 14, 2023 |
GRI BIO, INC. 2223 AVENIDA DE LA PLAYA, SUITE 208 LA JOLLA, CA 92037 GRI BIO, INC. 2223 AVENIDA DE LA PLAYA, SUITE 208 LA JOLLA, CA 92037 December 14, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jimmy McNamara and Laura Crotty, Office of Life Sciences Re: GRI Bio, Inc. Registration Statement on Form S-3 Filed on October 13, 2023, as amended on Form S-1 File No. 333-27497 |
|
| December 5, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| December 5, 2023 |
Exhibit 99.1 GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”) Clinical development plan potentially leveraging 505(b)(2) regulatory pathway Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no |
|
| December 4, 2023 |
Amended and Restated Non-Employee Director Compensation Program. Exhibit 10.28 GRI BIO, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (approved on August 10, 2023) Non-employee members of the board of directors (the “Board”) of GRI Bio, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). This Program has been adopted under the Company’s 2018 Equity Incentive Plan (th |
|
| December 4, 2023 |
3580 Carmel Mountain Road Suite 300 San Diego, CA 92130 858 314 1500 mintz.com December 4, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jimmy McNamara and Laura Crotty, Office of Life Sciences Re: GRI Bio, Inc. Registration Statement on Form S-3 Submitted October 13, 2023 File No. 333-274972 Ladies and Gentle |
|
| December 4, 2023 |
Exhibit 21.1 LIST OF SUBSIDIARIES Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization GRI Bio Operations, Inc. Delaware |
|
| December 4, 2023 |
As filed with the Securities and Exchange Commission on December 4, 2023. As filed with the Securities and Exchange Commission on December 4, 2023. Registration No. 333-274972 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 ON FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 2834 82-4369909 (State or other jurisd |
|
| December 4, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) GRI Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table I - Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry For |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employe |
|
| November 27, 2023 |
Exhibit 99.1 GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”) Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end Currently available treatments for IPF are limited to only two app |
|
| November 24, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2023 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employe |
|
| November 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employe |
|
| November 15, 2023 |
Exhibit 99.1 GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis ("IPF") on track to start before year end 2023; Interim data expected H1 2024 Currently available treatments for IPF are limited with only two approved drugs that come with significant side-effects, limited compliance a |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-40034 GRI BIO, INC. |
|
| November 14, 2023 |
Exhibit 10.3 GRI BIO, INC. CLAWBACK POLICY I. Introduction The Compensation Committee of the Board of Directors (the “Committee”) of GRI Bio, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. Th |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| October 13, 2023 |
As filed with the Securities and Exchange Commission on October 13, 2023 Registration No. |
|
| October 13, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) GRI Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table I - Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry For |
|
| August 25, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2023 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| August 25, 2023 |
A New Approach to Inflammatory Diseases NASDAQ: GRI | gribio.com August 2023 Corporate Presentation Exhibit 99.1 Forward Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of GRI Bio, Inc. (“GRI” or the “Company”). This presentation contains “forward-looking statements” within the meaning of the "s |
|
| August 23, 2023 |
Exhibit 99.1 GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights for the EU Aardvark to leverage ADAIR formulation technology for certain follow-on pipeline programs in development GRI to recei |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2023 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| August 23, 2023 |
Exhibit 10.1 Asset Purchase Agreement between GRI Bio, Inc. and Aardvark Therapeutics, Inc. THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of this 22nd day of August 2023 (“Effective Date”) between Aardvark Therapeutics, Inc., a company organized and existing under the laws of the State of Delaware, with its principal offices at 4747 Executive Drive, Suite 1020, San D |
|
| August 14, 2023 |
Employment Agreement, by and between the Company and Albert Agro, Ph.D., dated as of July 1, 2023. Exhibit 10.6 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made as of the 1st day of July, 2023 (the “Effective Date”), between GRI Bio, Inc. (the “Company”) and Albert Agro, PhD. (“Executive”), and shall become effective on the date provided herein. WHEREAS, the Company and Executive, in connection with the Merger, entered into a Consulting Agreement dated as of January 9, |
|
| August 14, 2023 |
Exhibit 99.1 GRI Bio (NASDAQ: GRI) Reports Second Quarter 2023 Financial Results and Provides Corporate Update Rapidly advancing clinical pipeline across multiple high-value inflammatory, fibrotic and autoimmune diseases On track to launch a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF before year end 2023 Ongoing progress towards completion of IND-enabling studies in SLE |
|
| August 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-40034 GRI BIO, INC. |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2023 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer Ide |
|
| July 6, 2023 |
GRI Bio, Inc. Balance Sheets (in thousands, except share and per share amounts) Exhibit 99.1 GRI Bio, Inc. Balance Sheets (in thousands, except share and per share amounts) March 31, 2023 December 31, 2022 (unaudited) Assets Current assets: Cash 460 $ 9 Prepaid expenses and other assets 271 299 Total current assets 731 308 Property and equipment, net 11 4 Operating lease right-of-use assets 55 67 Deposits 4 4 Total assets $ 801 $ 383 Liabilities and stockholders' deficit Curr |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2023 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Num |
|
| July 6, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Exhibit 99.4 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On April 21, 2023, pursuant to that Agreement and Plan of Merger, dated as of December 13, 2022, as amended on February 17, 2023 (the “Merger Agreement”), by and among GRI Bio, Inc., formerly known as Vallon Pharmaceuticals, Inc. (the “Company” or “Vallon”), GRI Operations, Inc., formerly known as GRI Bio, Inc., a Delaware co |
|
| July 6, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.3 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of GRI’s financial condition and results of operations should be read in conjunction with GRI’s financial statements and the related notes which are filed as Exhibit 99.1 of Amendment No. 2 to the Current Report on Form 8-K filed with the SEC on July 6, 2023. Som |
|
| July 6, 2023 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 99.2 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Shareholders of GRI Bio, Inc.: Opinion on the Financial Statements We have audited the accompanying balance sheets of GRI Bio, Inc. (“the Company”) as of December 31, 2022 and 2021, the related statements of operations, changes in stockholders’ deficit, and cash flows for each of the years in the two |
|
| June 7, 2023 |
GRI BIO, INC. 1,142,289 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-272276 PROSPECTUS GRI BIO, INC. 1,142,289 Shares of Common Stock This prospectus covers the offer and resale by the selling stockholder identified in this prospectus of up to 1,142,289 shares of our common stock, $0.0001 par value per share (the “Common Stock”), issuable upon the exercise of Series A-2 Warrants to purchase shares of Common Stoc |
|
| June 5, 2023 |
GRI BIO, INC. 2223 AVENIDA DE LA PLAYA, SUITE 208 LA JOLLA, CA 92037 GRI BIO, INC. 2223 AVENIDA DE LA PLAYA, SUITE 208 LA JOLLA, CA 92037 June 5, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Arzhang Navai Re: GRI Bio, Inc. Registration Statement on Form S-3 Filed May 30, 2023 File No. 333-272276 (the “Registration Statement”) Acceleration Request Ladies and Gentlemen: In |
|
| May 30, 2023 |
U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| May 30, 2023 |
As filed with the Securities and Exchange Commission on May 30, 2023 As filed with the Securities and Exchange Commission on May 30, 2023 Registration No. |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2023 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Num |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 26, 2023 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF GRI BIO, INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of the Corporation shall be fixed in the Certificate of Incorporation of the Corporation. Section 1.2 Other Offices. The Corporation may also have an office or offices, and keep the books and records of the Corporation, except as otherwi |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| May 15, 2023 |
A&R 2018 Equity Incentive Plan. Exhibit 4.1 GRI BIO, INC. 2018 EQUITY INCENTIVE PLAN (As amended and restated) 1. Establishment and Purpose. a. Establishment. GRI Bio, Inc. (formerly known as Vallon Pharmaceuticals, Inc.) (the “Company”) established the GRI Bio, Inc. 2018 Equity Incentive Plan (formerly known as the Vallon Pharmaceuticals, Inc. 2018 Equity Incentive Plan) (the “Plan”) effective as of October 1, 2018. The Plan is |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-40034 GRI BIO, INC. |
|
| May 3, 2023 |
Altium Capital Management, LP SC 13G Page 12 of 12 EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240. |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* GRI BIO, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 3622AW106 (CUSIP Number) April 24, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| May 2, 2023 |
US3622AW1069 / GRI BIO INC / TEP Biotech, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 GRI BIO, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 3622AW 106 (CUSIP Number) April 21, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| April 27, 2023 |
Exhibit 99.1 GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event - Live moderated webcast with members of the GRI Bio management team on Wednesday, May 3rd at 2:00 PM ET LA JOLLA, CA, April 27, 2023 – GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the tre |
|
| April 27, 2023 |
NASDAQ: GRI gribio.com Advancing Innovative NKT Cell Modulators to Transform the Treatment of Inflammatory, Fibrotic and Autoimmune Diseases Corporate Presentation April 2023 Exhibit 99.1 NASDAQ: GRI Forward Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of GRI Bio, Inc. (“GRI” or the “Company” |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer I |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 GRI BIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40034 82-4369909 (State or other jurisdiction (Commission File Number) (IRS Employer I |
|
| April 25, 2023 |
US3622AW1069 / GRI BIO INC / Agro Albert - SC 13D Activist Investment ——————————————————————————————————————————————— UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 25, 2023 |
US3622AW1069 / GRI BIO INC / Chaturvedi Vipin - SC 13D Activist Investment ——————————————————————————————————————————————— UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
